|
287 Companies |
|
339 Products |
|
339 Products |
|
208 Mechanisms of Action |
|
11 Trials |
|
3331 News |
|
| «12345678910111213...6869» |
- | Enrollment closed, Head-to-Head: SALPINGOVA: Effect of Salpingectomy During Conservative Hysterectomy (clinicaltrials.gov) - Oct 31, 2017
P=N/A, N=350, Active, not recruiting, Sponsor: University Hospital, Tours
Recruiting --> Active, not recruiting
- | sildenafil / Generic mfg.
Enrollment change, Trial withdrawal: Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer (clinicaltrials.gov) - Oct 27, 2017
P1, N=0, Withdrawn, Sponsor: The University of Texas Medical Branch, Galveston
Recruiting --> Active, not recruiting N=40 --> 0 | Recruiting --> Withdrawn
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. (clinicaltrials.gov) - Oct 26, 2017
P3, N=370, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
N=40 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Feb 2016 --> Dec 2018
- | cabazitaxel / Generic mfg.
Trial completion: Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (clinicaltrials.gov) - Oct 26, 2017
P2, N=24, Completed, Sponsor: University of Ulm
Trial primary completion date: Feb 2016 --> Dec 2018 Active, not recruiting --> Completed
- | temozolomide / Generic mfg.
Trial primary completion date: MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Oct 25, 2017
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: May 2010 --> Jan 2018
- Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Enrollment change, Trial primary completion date, Metastases: Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) (clinicaltrials.gov) - Oct 25, 2017
P1, N=10, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2010 --> Jan 2018 Active, not recruiting --> Completed | N=22 --> 10 | Trial primary completion date: Nov 2018 --> Oct 2017
- Korlym (mifepristone) / Corcept Therap
Trial primary completion date, Combination therapy, Metastases: Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors (clinicaltrials.gov) - Oct 19, 2017
P1, N=37, Active, not recruiting, Sponsor: Corcept Therapeutics
Active, not recruiting --> Completed | N=22 --> 10 | Trial primary completion date: Nov 2018 --> Oct 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- | AMG 337 / ImmunityBio, Amgen
Phase classification, Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer (clinicaltrials.gov) - Oct 19, 2017
P2, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Sep 2017 --> Dec 2017 Phase classification: P1/2 --> P2 | N=308 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Mar 2018
- | Trial primary completion date: Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=140, Active, not recruiting, Sponsor: University of Rochester
Phase classification: P1/2 --> P2 | N=308 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Mar 2018 Trial primary completion date: Jun 2017 --> Nov 2017
- | temozolomide / Generic mfg.
Trial primary completion date: MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Oct 16, 2017
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2017 --> Nov 2017 Trial primary completion date: Jan 2018 --> May 2010
- | veliparib (ABT-888) / AbbVie
Trial primary completion date, BRCA Biomarker, PARP Biomarker: Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (clinicaltrials.gov) - Oct 16, 2017
P1, N=98, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2018 --> May 2010 Trial primary completion date: Jun 2016 --> May 2011
- | everolimus / Generic mfg.
Biomarker, Trial completion, Trial primary completion date, Metastases: Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers (clinicaltrials.gov) - Oct 4, 2017
P=N/A, N=20, Completed, Sponsor: St. Joseph's Healthcare Hamilton
Trial primary completion date: Jun 2016 --> May 2011 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=15, Terminated, Sponsor: Burzynski Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Oct 2017 N=40 --> 15 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; slow accrual
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors (clinicaltrials.gov) - Sep 29, 2017
P2, N=1, Terminated, Sponsor: Burzynski Research Institute
N=40 --> 15 | Initiation date: Aug 1998 --> Mar 1996 | Active, not recruiting --> Terminated; slow accrual N=40 --> 1 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual
- | sirolimus / Generic mfg.
Trial completion, Metastases: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
N=40 --> 1 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma (clinicaltrials.gov) - Sep 28, 2017
P2, N=3, Terminated, Sponsor: Burzynski Research Institute
Active, not recruiting --> Completed N=40 --> 3 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual
- | Trial completion, Trial primary completion date, HEOR: Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=14, Completed, Sponsor: City of Hope Medical Center
N=40 --> 3 | Initiation date: Aug 1998 --> Dec 1996 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2017
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination: (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma (clinicaltrials.gov) - Sep 27, 2017
P2, N=7, Terminated, Sponsor: Western Regional Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Sep 2017 N=88 --> 7 | Recruiting --> Terminated; PI Decision
- | Immuncell-LC (GCC4002) / GC Biopharma
Trial completion, Trial primary completion date, Metastases, Immune cell: Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC (clinicaltrials.gov) - Sep 27, 2017
P2, N=40, Completed, Sponsor: Green Cross Cell Corporation
N=88 --> 7 | Recruiting --> Terminated; PI Decision Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017
- pazopanib / Generic mfg.
Trial primary completion date, Metastases: Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer (clinicaltrials.gov) - Sep 21, 2017
P2, N=46, Recruiting, Sponsor: Hellenic Cooperative Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jul 2017 Trial primary completion date: Feb 2017 --> Apr 2019
- | Trial completion, CAR T-Cell Therapy, Metastases: Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer (clinicaltrials.gov) - Sep 19, 2017
P1, N=16, Completed, Sponsor: University of Pennsylvania
Trial primary completion date: Feb 2017 --> Apr 2019 Active, not recruiting --> Completed
- alisertib (MLN8237) / Puma
Trial primary completion date, Metastases: Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Sep 14, 2017
P1, N=42, Active, not recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Dec 2017
- || duligotuzumab (MEHD7945A) / Roche
Trial primary completion date: A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors (clinicaltrials.gov) - Sep 12, 2017
P1, N=66, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Aug 2017 --> Dec 2013
- | capecitabine / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma (clinicaltrials.gov) - Sep 11, 2017
P2, N=57, Completed, Sponsor: Southwest Oncology Group
Trial primary completion date: Aug 2017 --> Dec 2013 No longer recruiting --> Completed
- | Enrollment change, Trial termination, Trial primary completion date: Whipple Procedure: Standard of Care vs. Thunderbeat (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=44, Terminated, Sponsor: Washington University School of Medicine
No longer recruiting --> Completed N=60 --> 44 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Aug 2017; Principal Investigator and Study Sponsor decided to terminate the study early
- |||| carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Enrollment change, Combination therapy, Metastases: ABOUND 70+: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (clinicaltrials.gov) - Sep 11, 2017
P4, N=143, Completed, Sponsor: Celgene
N=60 --> 44 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Aug 2017; Principal Investigator and Study Sponsor decided to terminate the study early Active, not recruiting --> Completed | N=280 --> 143
- | Trial primary completion date: Systems Intervention to Promote Colorectal Cancer (CRC) Screening (clinicaltrials.gov) - Sep 8, 2017
P=N/A, N=3186, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | N=280 --> 143 Trial primary completion date: Aug 2017 --> Aug 2018
- | Avastin (bevacizumab) / Roche
Phase classification, Trial initiation date: Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab (clinicaltrials.gov) - Sep 8, 2017
P2, N=30, Not yet recruiting, Sponsor: University of Utah
Trial primary completion date: Aug 2017 --> Aug 2018 Phase classification: P=N/A --> P2 | Initiation date: Jan 2017 --> Jan 2018
- | polyvalent vaccine-KLH conjugate / MabVax
Trial completion, Trial primary completion date: OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission (clinicaltrials.gov) - Sep 6, 2017
P2, N=171, Completed, Sponsor: Gynecologic Oncology Group
Phase classification: P=N/A --> P2 | Initiation date: Jan 2017 --> Jan 2018 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015
- | Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
Trial completion, Trial primary completion date, Combination therapy, Metastases: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Sep 6, 2017
P2, N=88, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2017
- Trial termination, Trial primary completion date: ONC003: Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=227, Terminated, Sponsor: Myriad Genetic Laboratories, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2017 Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; Company decision to terminate
- | Enrollment change, Trial withdrawal, Trial primary completion date: Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 31, 2017
P=N/A, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2017; Company decision to terminate N=238 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2016 --> Mar 2014
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=27, Completed, Sponsor: Gynecologic Oncology Group
N=238 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2016 --> Mar 2014 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- | Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, IMNN-001 / Imunon
Trial primary completion date, Combination therapy: EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=16, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Trial primary completion date: Dec 2014 --> Jul 2015
- | erlotinib / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer (clinicaltrials.gov) - Aug 24, 2017
P2, N=24, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Jun 2017 --> Nov 2017
- epacadostat (INCB024360) / Incyte
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 24, 2017
P1, N=2, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jun 2017 --> Nov 2017 Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015
- | capecitabine / Generic mfg.
Trial completion: Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer (clinicaltrials.gov) - Aug 23, 2017
P2, N=21, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Completed | N=20 --> 2 | Initiation date: Apr 2014 --> Jul 2014 | Trial primary completion date: Aug 2017 --> Nov 2015 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma (clinicaltrials.gov) - Aug 23, 2017
P2, N=19, Completed, Sponsor: Burzynski Research Institute
Active, not recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Children With Visual Pathway Glioma (clinicaltrials.gov) - Aug 23, 2017
P2, N=12, Completed, Sponsor: Burzynski Research Institute
Recruiting --> Completed Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma (clinicaltrials.gov) - Aug 23, 2017
P2, N=27, Completed, Sponsor: Burzynski Research Institute
Recruiting --> Completed Recruiting --> Completed
- | Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Metastases: FLIPPER: First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Aug 23, 2017
P4, N=44, Completed, Sponsor: iOMEDICO AG
Recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors (clinicaltrials.gov) - Aug 23, 2017
P=N/A, N=0, No Longer Available, Sponsor: Andrei Iagaru
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- | MK-2206 / Merck (MSD), dinaciclib (MK-7965) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 22, 2017
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | N=54 --> 42 | Trial primary completion date: Jan 2017 --> Jul 2016
- | Trial primary completion date, HEOR: Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=14, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=54 --> 42 | Trial primary completion date: Jan 2017 --> Jul 2016 Trial primary completion date: Nov 2017 --> Apr 2018
- | temozolomide / Generic mfg.
Enrollment closed, Trial initiation date, Trial primary completion date: Spatial Analysis and Validation of Glioblastoma on 7 T MRI (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Maastricht Radiation Oncology
Trial primary completion date: Nov 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Initiation date: May 2015 --> Dec 2014 | Trial primary completion date: Sep 2017 --> Jan 2019
- | p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Aug 22, 2017
P1, N=9, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Initiation date: May 2015 --> Dec 2014 | Trial primary completion date: Sep 2017 --> Jan 2019 Trial primary completion date: Sep 2017 --> Aug 2018
- | Phase classification: A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (clinicaltrials.gov) - Aug 21, 2017
P=N/A, N=1208, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Sep 2017 --> Aug 2018 Phase classification: P1 --> P=N/A
- | Herceptin (trastuzumab) / Roche
Trial completion: GATE 1: Trial Evaluating Combined Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 21, 2017
P2, N=63, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Phase classification: P1 --> P=N/A Recruiting --> Completed
- | lifastuzumab vedotin (DNIB0600A) / Roche
Trial termination: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Aug 21, 2017
P2, N=95, Terminated, Sponsor: Genentech, Inc.
Recruiting --> Completed Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria.
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion, Trial primary completion date, Combination therapy, Surgery, Metastases: 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Aug 18, 2017
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; The primary objective of PFS did not meet pre-specified criteria. Active, not recruiting --> Completed | Trial primary completion date: May 2011 --> Dec 2012